Who Owns Globus Medical Company?

Globus Medical Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Globus Medical Company?

Understanding a company's ownership is key to grasping its strategic direction and market influence. A significant shift occurred with the merger of Globus Medical Company and NuVasive, Inc., finalized on September 1, 2023.

This substantial all-stock transaction, valued at around $3.1 billion, created a major player in musculoskeletal procedural solutions.

Globus Medical, founded in 2003, specializes in innovative musculoskeletal implants and surgical instruments, particularly for spinal disorders. They also focus on integrating robotic and enabling technologies to improve surgical outcomes. Following the merger, the combined entity became the second-largest spine technology company worldwide, capturing about 21% of the global spine market share. As of August 20, 2025, Globus Medical's market capitalization is approximately $8.26 billion USD. This evolution traces from its founder's initial stake to its current public shareholders and the impact of the NuVasive merger, which also influences its product development, as seen in the Globus Medical PESTEL Analysis.

Globus Medical, Inc. was co-founded in March 2003 by David C. Paul, David D. Davidar, and Andrew Iott. David C. Paul, who also served as the company's initial CEO, transitioned to Executive Chairman in August 2017. His prior experience included product development and marketing at a Swiss medical device maker.

Founding Team

Globus Medical was established in March 2003 by David C. Paul, David D. Davidar, and Andrew Iott. This core group laid the foundation for the company's future growth.

Leadership Transition

David C. Paul, a key founder, served as CEO until August 2017. He then moved to the role of Executive Chairman, continuing his influence on the company's strategic direction.

Early Financial Support

Significant early financial backing came from a Series E funding round in August 2007, which secured $110 million. Goldman Sachs was among the notable investors in this round.

Legal Challenges

The company navigated early legal disputes, including a 2004 lawsuit from Synthes that was settled in August 2007 for $13.5 million. Another legal matter in 2011 resulted in a $16 million payment in 2013.

Voting Power Structure

Following its IPO, Globus Medical utilized a dual-class share system. This structure granted David C. Paul substantial voting control, approximately 82% of the total voting power.

Founder Control

A voting agreement from June 14, 2004, further solidified founder control. This agreement provided David C. Paul with an irrevocable proxy to vote certain stockholders' shares.

The initial ownership structure of Globus Medical was significantly influenced by its founders, particularly David C. Paul, through a dual-class share system that concentrated voting power. This arrangement was designed to maintain the founders' vision for the company's strategic direction, as detailed in our discussion on the Mission, Vision & Core Values of Globus Medical.

Key Aspects of Early Ownership

The early days of Globus Medical were marked by founder-driven control and significant financial maneuvers. Understanding these foundational elements is crucial for comprehending the company's trajectory and current ownership landscape.

• Co-founders: David C. Paul, David D. Davidar, and Andrew Iott.
• David C. Paul's leadership: CEO until August 2017, then Executive Chairman.
• Early funding: $110 million raised in a Series E round in August 2007, including investment from Goldman Sachs.
• Legal settlements: Payments totaling $13.5 million in 2007 and $16 million in 2013 to resolve disputes.
• Voting control: David C. Paul held approximately 82% of the voting power post-IPO due to a dual-class share structure.
• Founder influence: A 2004 voting agreement granted David C. Paul an irrevocable proxy for certain shares.

Globus Medical SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

The ownership structure of Globus Medical has been significantly reshaped by its merger with NuVasive, Inc., a transaction that became effective on September 1, 2023. This strategic combination created a new entity where former Globus Medical shareholders now hold the majority of the combined company's stock.

As of April 2025, institutional investors are the primary holders of Globus Medical's Class A common stock, collectively owning 82.91%. This significant institutional ownership, with mutual funds alone holding 70.11% in April 2025, indicates a strong reliance on large investment firms for the company's capital. Insider holdings, representing ownership by company executives and directors, accounted for a smaller portion at 0.82% in April 2025. The market capitalization has seen considerable movement, increasing by 53.38% from $7.34 billion in December 2023 to $11.27 billion in December 2024, though it later decreased to approximately $8.26 billion by August 20, 2025, a 11.48% drop over the preceding year. These shifts in ownership and valuation underscore the dynamic nature of the company's financial landscape and its position within the broader market, influencing its strategic direction and governance. Understanding who owns Globus Medical is crucial for assessing its future trajectory and potential growth, especially in light of its recent Competitors Landscape of Globus Medical.

Key Stakeholders in Globus Medical

Institutional investors are the dominant force in Globus Medical's ownership structure. Their substantial holdings often translate into significant influence over company decisions and strategic planning.

• Institutional Investors: Own 82.91% of Class A common stock as of April 2025.
• Mutual Funds: Increased their stake to 70.11% in April 2025.
• Major Institutional Holders: Include The Vanguard Group, BlackRock, Goldman Sachs, State Street Global Advisors, and Janus Henderson Group.
• Insider Holdings: Represent 0.82% of ownership as of April 2025.

Globus Medical PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The current Board of Directors for Globus Medical, Inc. is comprised of eleven members, reflecting an expansion from eight following the merger with NuVasive. This board structure includes long-standing leadership and new appointees, ensuring a diverse range of expertise in guiding the company's strategic direction.

Globus Medical's ownership structure is significantly influenced by its dual-class share system. Class A common stock grants one vote per share, while Class B common stock offers ten votes per share. This arrangement historically concentrated voting power, with co-founder David C. Paul holding approximately 82% of the total voting power at the time of the company's IPO. While the merger introduced new shareholders, this dual-class structure continues to provide substantial insider influence over critical corporate decisions, with no recent public reports indicating significant shifts due to activist investors.

Understanding Voting Power

The dual-class share structure is a key element in understanding who owns Globus Medical and how control is exercised. This system differentiates voting rights, impacting the influence of different shareholder groups.

• Class A shares: 1 vote per share.
• Class B shares: 10 votes per share.
• David C. Paul, a co-founder, historically held significant voting power.
• This structure ensures continued insider influence on corporate governance.
• Understanding this is crucial for assessing Globus Medical stock ownership.

Globus Medical Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

The ownership landscape of Globus Medical has seen significant shifts, most notably with its merger with NuVasive, Inc. This strategic move, finalized in September 2023, redefined the shareholder base, with former NuVasive shareholders now holding approximately 28% of the combined entity.

Recent executive leadership changes have occurred, with Keith Pfeil assuming the role of President and Chief Executive Officer on July 18, 2025. This transition follows Daniel Scavilla's resignation. Concurrently, Kyle Kline was appointed Senior Vice President and Chief Financial Officer, further shaping the company's leadership team.

Shareholder Value Enhancement

A $500 million share repurchase program was announced on May 15, 2025. This initiative aims to address market valuation discrepancies and bolster shareholder value.

Institutional Investor Activity

As of April 2025, institutional investors held 82.91% of the company's Class A common stock. There's been active portfolio management, with numerous institutions adjusting their holdings.

Merger Impact on Ownership

The 2023 merger with NuVasive, Inc. resulted in a significant ownership realignment. Globus Medical shareholders now hold approximately 72% of the combined entity.

Leadership Transition

The recent appointment of Keith Pfeil as CEO signifies a new chapter in executive leadership. This change is part of the company's ongoing strategic evolution, impacting its Target Market of Globus Medical and operational direction.

Globus Medical Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔